Pooled Data on NT-501 Presented at RWC

Neurotech's Encelto is the first FDA-approved therapy for patients with macular telangiectasia.

By: W. Lloyd Clark, MD

Retinal Physician May 9, 2025

5 Key Takeaways

1

Encelto is the first FDA-approved therapy for macular telangiectasia, affecting approximately 150,000 people in the U.S.
2

The NT-501 implant contains genetically engineered RPE cells that produce therapeutic proteins for targeted treatment.
3

Pooled analysis from three clinical trials showed NT-501 significantly reduced ellipsoid zone loss compared to placebo.
4

Patients with the NT-501 implant exhibited significantly improved reading speed and slowed loss of retinal sensitivity.
5

The NT-501 device represents a groundbreaking treatment option for patients with MacTel, with commercial availability expected soon.

W. Lloyd Clark

Bio: W. Lloyd Clark, MD, contributed to a Retinal Physician report examining discordances in perceptions of shared decision-making among patients with age-related macular degeneration, diabetic retinopathy/diabetic macular edema, and retinal vein occlusion and their care teams. The article focused on patient-provider communication, adherence to anti-VEGF therapy, and collaborative learning to improve shared decision-making in retinal disease care.

Contributions:

https://retinalphysician.com/issues/2022/may/discordances-in-perceptions-of-shared-decision-making-among-patients-with-retinal-diseases-and-their-care-teams/

PentaVision

Retinal Physician

Pooled Data on NT-501 Presented at RWC

5 Key Takeaways

1

2

3

4

5

Recommendations